Abstract
Pregnancy induces physiological changes that can alter drug disposition, yet little is known about their impact on renal transporters such as organic anion transporters 1 and 3 (OAT1/3). This study aimed to evaluate the in vivo activity of OAT1/3 during pregnancy using furosemide as a probe substrate. Twelve healthy non-pregnant women and 10 healthy pregnant women, mostly in the third trimester, received a single 40-mg oral dose of furosemide under fasting conditions. Serial blood and urine samples were collected for up to 24 h. Pharmacokinetic parameters were estimated by non-compartmental analysis, including time to maximum plasma concentration (t(max)), maximum plasma concentration (C(max)), area under the plasma concentration-time curve (AUC), amount excreted in urine (Ae), fraction excreted unchanged in urine (f(e)), unbound plasma fraction (fu), apparent clearance (CL/F), renal clearance (CL(R)), non-renal clearance (CL(NR)), secretory clearance (CL(SEC)), and metabolic clearance via furosemide glucuronide formation (CL(M)). Compared with non-pregnant women, pregnant women exhibited significantly lower exposure, C(max), Ae, and f(e) values, while CL/F and CL(NR) were significantly increased. In contrast, no significant differences were observed for CL(R) and CL(SEC,) indicating preserved OAT1/3 activity. These findings suggest unchanged OAT1/3-mediated renal secretory activity during pregnancy contrast with the published literature for other OAT1/3 substrates, which have, in most cases, reported an increase in OAT1/3 activity during pregnancy. Instead, the data raise the hypothesis that changes in intestinal absorption of furosemide, possibly influenced by gestational regulation of intestinal transporters, may contribute to the lower exposure.